Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics (OTCPink: APLIF), a biopharmaceutical company specializing in infectious diseases and biodefense drug development, held its annual and special meeting of shareholders with all proposed resolutions receiving approval.
The shareholders elected six directors to the board with overwhelming support, each receiving over 99% approval: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd. Additionally, shareholders approved the reappointment of PricewaterhouseCoopers as auditors, and endorsed the company's rolling 10% stock option plan and equity incentive plan.
Appili Therapeutics (OTCPink: APLIF), una società biofarmaceutica specializzata in malattie infettive e nello sviluppo di farmaci per la difesa biodei
fensiva, ha tenuto la sua assemblea annuale e straordinaria degli azionisti, con l'approvazione di tutte le proposte. Gli azionisti hanno eletto sei membri del consiglio di amministrazione con un sostegno schiacciante, ognuno con oltre 99% di approvazione: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni e Prakash Gowd. Inoltre, gli azionisti hanno approvato la riconferma di PricewaterhouseCoopers come revisori dei conti e hanno approvato il piano di opzioni azionarie del 10% in corso e il piano di incentivi azionari dell'azienda.Appili Therapeutics (OTCPink: APLIF), una empresa biofarmacéutica especializada en enfermedades infecciosas y desarrollo de fármacos para defensa biológica, celebró su asamblea anual y extraordinaria de accionistas, y todas las resoluciones propuestas fueron aprobadas. Los accionistas eligieron a seis directores para la junta con un apoyo abrumador, cada uno con más del 99% de aprobación: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni y Prakash Gowd. Además, los accionistas aprobaron la reelección de PricewaterhouseCoopers como auditores y respaldaron el plan de opciones sobre acciones del 10% en curso y el plan de incentivos de capital de la empresa.
Appili Therapeutics (OTCPink: APLIF)는 감염병 및 생물방어 신약 개발을 전문으로 하는 생물제약 회사로, 주주 연례 및 특별 회의를 개최했고 모든 제안된 안건이 승인되었습니다. 주주는 이사회에 6명의 이사를 압도적 지지로 선출했으며, 각 이사는 99% 이상 승인을 받았습니다: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni 및 Prakash Gowd. 또한 주주들은 PricewaterhouseCoopers를 감사인으로 재선하는 것을 승인했고, 회사의 10% 주식매수선택권 계획과 주식 보상 계획의 롤링 형태를 승인했습니다.
Appili Therapeutics (OTCPink: APLIF), une société biopharmaceutique spécialisée dans les maladies infectieuses et le développement de médicaments pour la défense biologique, a tenu son assemblée annuelle et extraordinaire des actionnaires, et toutes les résolutions proposées ont été approuvées. Les actionnaires ont élu six administrateurs au conseil avec un soutien écrasant, chacun obtenant plus de 99% d'approbation : Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni et Prakash Gowd. De plus, les actionnaires ont approuvé la réélection de PricewaterhouseCoopers en tant qu'auditeurs et ont approuvé le plan d'options sur actions à hauteur de 10% et le plan d'incitation en capitaux de l'entreprise.
Appili Therapeutics (OTCPink: APLIF), ein biopharmazeutisches Unternehmen, das sich auf Infektionskrankheiten und die Entwicklung von Medikamenten zum Biowaffenschutz spezialisiert hat, hielt seine jährliche und außerordentliche Hauptversammlung ab, wobei alle vorgeschlagenen Beschlüsse Zustimmung fanden. Die Aktionäre wählten sechs Direktoren in den Vorstand mit überwältigendem Rückhalt, jeder erhielt über 99% Zustimmung: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni und Prakash Gowd. Außerdem bestätigten die Aktionäre PricewaterhouseCoopers erneut als Wirtschaftsprüfer und befürworteten den rollierenden 10%-Aktienoptionsplan sowie den Beteiligungsplan des Unternehmens.
Appili Therapeutics (OTCPink: APLIF)، هي شركة تقنيات حيوية دوائية تتخصص في الأمراض المعدية وتطوير أدوية للدفاع البيولوجي، عقدت اجتماعها السنوي والخاص للمساهمين، ووافقت على جميع القرارات المقترحة. اختار المساهمون ستة مديرين للمجلس ب دعم ساحق، حيث حصل كل واحد منهم على أكثر من 99% من الموافقة: دن سِيلا، بريان بلوم، تيريزا ماتكوفيتس، يورجين فرهليخ، أرماند بالبوْني، وبراہك غود. كما وافق المساهمون على إعادة تعيين PricewaterhouseCoopers كمراجعين، ووافقوا على خطة خيارات الأسهم بنسبة 10% وخطة الحوافز بالأسهم للشركة.
Appili Therapeutics (OTCPink: APLIF)，一家专注于传染病与生物防御药物开发的生物制药公司，举行了年度及特别股东大会，所有提案均获通过。股东以压倒性支持选举了六名董事进入董事会，每人获批超过99%：Don Cilla、Brian Bloom、Theresa Matkovits、Juergen Froehlich、Armand Balboni 与 Prakash Gowd。此外，股东批准将 PricewaterhouseCoopers 重新任命为审计师，并支持公司的滚动10%股票期权计划及股权激励计划。
- Strong shareholder support with all directors receiving over 99% approval votes
- Approval of stock option and equity incentive plans provides flexibility for talent retention
- None.
HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today (the “Meeting”).
Based on the proxies received and the vote conducted at the Meeting, all tabled resolutions were approved by the shareholders of the Company (the “Shareholders”), including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.
Voting results for each director are summarized below:
| Name of Nominee | Votes For | Votes Against/Withheld |
| Don Cilla | 23,473,607 ( | 144,875 ( |
| Brian Bloom | 23,479,607 ( | 138,875 ( |
| Theresa Matkovits | 23,581,692 ( | 36,790 ( |
| Juergen Froehlich | 23,581,692 ( | 36,790 ( |
| Armand Balboni | 23,473,607 ( | 144,875 ( |
| Prakash Gowd | 23,581,692 ( | 36,790 ( |
In addition to the election of the directors of the Company as noted above, the Shareholders:
- re-appointed PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration;
- approved unallocated options, rights or other entitlements under the Company’s rolling
10% stock option plan; and - approved unallocated awards, rights or other entitlements under the Company’s equity incentive plan.
The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR+ profile at www.sedarplus.ca.
About Appili Therapeutics
Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat, and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the center of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, President and CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
Who are the newly elected directors of Appili Therapeutics (APLIF)?
What key resolutions were approved at Appili Therapeutics' 2025 annual meeting?
What was the voting percentage for Appili Therapeutics' director elections?
Where can investors find detailed voting results for Appili Therapeutics' annual meeting?
